Usefulness of epoprostenol therapy in the severely ill adolescent/adult with Eisenmenger physiology (Q44341514)

2 December 2017

title

Usefulness of epoprostenol therapy in the severely ill adolescent/adult with Eisenmenger physiology (English)

1 reference

2 December 2017

1 reference

0 references

2

Jane W Newburger

1 reference

2 December 2017

6

Kimberlee Gauvreau

1 reference

2 December 2017

Susan M Fernandes

1

1 reference

2 December 2017

Peter Lang

3

1 reference

2 December 2017

Dorothy D Pearson

4

1 reference

2 December 2017

Jeffrey A Feinstein

5

1 reference

2 December 2017

Michael J Landzberg

7

1 reference

2 December 2017

language of work or name

English

0 references

publication date

1 March 2003

1 reference

American Journal of Cardiology

2 December 2017

published in

1 reference

2 December 2017

volume

91

1 reference

2 December 2017

issue

5

1 reference

2 December 2017

page(s)

632-635

1 reference

Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial

2 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903328-3

A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903328-3

Vasodilator therapy for primary pulmonary hypertension in children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903328-3

Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903328-3

Primary pulmonary hypertension between inflammation and cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903328-3

Primary pulmonary hypertension: a vascular biology and translational research "Work in progress".

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903328-3

Abnormal endothelial factor VIII associated with pulmonary hypertension and congenital heart defects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903328-3

Endothelin-1 in the lungs of patients with pulmonary hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903328-3

Inhaled nitric oxide in congenital heart disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903328-3

Enhanced expression of vascular endothelial growth factor in pulmonary plexogenic arteriopathy due to congenital heart disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903328-3

Prostaglandins, ductus arteriosus, pulmonary circulation: current concepts and clinical potential

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903328-3

Aerosolized prostacyclin for preoperative evaluation and post-cardiosurgical treatment of patients with pulmonary hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903328-3

10.1016/S0002-9149(02)03328-3

7 January 2021

Identifiers

DOI

1 reference

2 December 2017

1 reference